Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | MAOB | P27338 | 4/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7650509 | 0.93 | GFER (0.59) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL332100 | 0.85 | GFER (0.42) | GFERMAOBMAOAALDH1A1TAAR1 | |
| SCHEMBL10474666 | 0.84 | GFER (0.62) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL7528298 | 0.83 | TAAR1 (0.56) | MAOBALDH1A1TSHRTDP1LOXL2 | |
| SCHEMBL9472520 | 0.82 | MAOB (0.64) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL8164156 | 0.82 | GFER (1.00) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL187043 | 0.82 | GFER (1.00) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL3482833 | 0.82 | GFER (1.00) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL8653872 | 0.79 | GFER (0.93) | GFERMAOBMAOAALDH1A1CYP3A4 | |
| SCHEMBL12110702 | 0.77 | GFER (0.77) | GFERMAOBMAOAALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023012820-A1 | A PROCESS FOR THE PREPARATION OF GRAPIPRANT AND ITS INTERMEDIATES | ZENFOLD SUSTAINABLE TECHNOLOGIES PRIVATE LIMITED (IN) | 2023-02-09 | — | — | WO | disclosed |
| US-7348315-B2 | Methods of treating heart failure with modified ATP, ADP and AMP compounds | THE UNIVERSITY OF CONNECTICUT (US) | 2008-03-25 | — | — | US | disclosed |
| US-20030186929-A1 | Methods of treating heart failure with modified ATP, ADP and AMP compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186929-A1 | Methods of treating heart failure with modified ATP, ADP and AMP compounds | ATP5MF, ATP5MG, ATP2A1 | GFER 1372/4885MAOB 1689/4885MAOA 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.